203 related articles for article (PubMed ID: 32810173)
1. 3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors.
Badder LM; Hollins AJ; Herpers B; Yan K; Ewan KB; Thomas M; Shone JR; Badder DA; Naven M; Ashelford KE; Hargest R; Clarke AR; Esdar C; Buchstaller HP; Treherne JM; Boj S; Ramezanpour B; Wienke D; Price LS; Shaw PH; Dale TC
PLoS One; 2020; 15(8):e0235319. PubMed ID: 32810173
[TBL] [Abstract][Full Text] [Related]
2. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
Jang MK; Mashima T; Seimiya H
Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
[TBL] [Abstract][Full Text] [Related]
3. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
[TBL] [Abstract][Full Text] [Related]
4. Targeting Tankyrase to Fight WNT-dependent Tumours.
Thorvaldsen TE
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
[TBL] [Abstract][Full Text] [Related]
5. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
[TBL] [Abstract][Full Text] [Related]
6. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Elbadawy M; Hayashi K; Ayame H; Ishihara Y; Abugomaa A; Shibutani M; Hayashi SM; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Shinohara Y; Kaneda M; Yamawaki H; Usui T; Sasaki K
Biomed Pharmacother; 2021 Oct; 142():112043. PubMed ID: 34411919
[TBL] [Abstract][Full Text] [Related]
10. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
[TBL] [Abstract][Full Text] [Related]
12. Sphere‑forming assay vs. organoid culture: Determining long‑term stemness and the chemoresistant capacity of primary colorectal cancer cells.
Zhao H; Yan C; Hu Y; Mu L; Huang K; Li Q; Li X; Tao D; Qin J
Int J Oncol; 2019 Mar; 54(3):893-904. PubMed ID: 30664193
[TBL] [Abstract][Full Text] [Related]
13. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.
Cho YH; Ro EJ; Yoon JS; Mizutani T; Kang DW; Park JC; Il Kim T; Clevers H; Choi KY
Nat Commun; 2020 Oct; 11(1):5321. PubMed ID: 33087710
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
15. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
[TBL] [Abstract][Full Text] [Related]
16.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
17. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
[TBL] [Abstract][Full Text] [Related]
18. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
19. Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling.
Hu X; Zhang L; Li Y; Ma X; Dai W; Gao X; Rao X; Fu G; Wang R; Pan M; Guo Q; Xu X; Zhou Y; Gao J; Zhang Z; Cai S; Peng J; Hua G
EBioMedicine; 2020 Jun; 56():102800. PubMed ID: 32512510
[TBL] [Abstract][Full Text] [Related]
20. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
